Related Experiment Video

Updated: Sep 5, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.0K

Review and Practical Guidance on Managing Fungal Infections in Patients With Psoriasis Receiving Anti-IL-17 Therapies

Jensen Yeung1,2,3,4,5, Paul E Bunce6, Charles W Lynde2,5,7

  • 112366 Faculty of Medicine, University of Toronto, Toronto, ON, Canada.

Journal of Cutaneous Medicine and Surgery
|July 12, 2022
PubMed

Insights

Interleukin-17 (IL-17) biologics effectively treat plaque psoriasis but increase risks of fungal infections, particularly Candida. Patients and doctors must recognize and manage these Candida infections.

Area of Science:

  • Immunology
  • Dermatology
  • Infectious Diseases

Background:

  • The interleukin-17 (IL-17) signaling pathway is crucial in plaque psoriasis pathogenesis.
  • IL-17 blockade is an effective psoriasis treatment but impairs antifungal immunity.
  • This leads to increased rates of fungal infections, especially Candida albicans, in patients.

Purpose of the Study:

  • To review Candida infection rates in patients using IL-17 biologics.
  • To discuss clinical presentations of candidiasis in this population.
  • To propose management strategies for Candida infections.

Main Methods:

  • Literature review of clinical trials and real-world data on IL-17 biologics.
  • Analysis of reported Candida infection incidence.
  • Synthesis of information on clinical manifestations and treatment.

Main Results:

  • IL-17 biologics are associated with a higher incidence of Candida infections.
  • Common presentations include mucocutaneous candidiasis.
  • Data from clinical trials and real-world practice confirm this risk.

Conclusions:

  • Awareness of increased Candida infection risk is essential for patients and physicians.
  • Prompt recognition and appropriate management are key.
  • IL-17 blockade requires careful monitoring for opportunistic fungal infections.
Keywords:
anti-IL-17biologicscandidiasismanagementpsoriasis

More Related Videos

Th17 Inflammation Model of Oropharyngeal Candidiasis in Immunodeficient Mice08:02

Th17 Inflammation Model of Oropharyngeal Candidiasis in Immunodeficient Mice

Published on: February 18, 2015

10.1K
Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture10:31

Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture

Published on: April 8, 2016

14.7K

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
260
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
176
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
197
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
226
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
402